Overview

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Patients With PBC

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC).
Phase:
Phase 2
Details
Lead Sponsor:
Intercept Pharmaceuticals
Treatments:
Bezafibrate
Chenodeoxycholic Acid